Agenus Announces Data From Phase II Study of BOT+BAL in Combination with Agent-797 in PD-1 Refractory Gastroesophageal Cancer to Be Presented at AACR 2026

Key Takeaways

• Phase II trial combines BOT, BAL, agenT‑797.
• Targets PD‑1‑refractory gastroesophageal cancer.
• Data to be presented at AACR 2026 meeting.
• BOT has treated ~1,200 patients in early trials.
• BAL evaluated in >900 patients, showing favorable safety.

Summary

Agenus announced that data from an investigator‑initiated Phase II trial of its multi‑mechanistic immunotherapy combo—botensilimab (BOT), balstilimab (BAL) and the allogeneic iNKT cell therapy agenT‑797—will be presented at the AACR Annual Meeting in April 2026. The study targets patients with PD‑1‑refractory gastroesophageal cancer, a cohort with limited therapeutic options. BOT and BAL have collectively been evaluated in over 2,100 patients across Phase I/II trials, showing activity in multiple tumor types. Dr. Samuel L. Cytyrn will deliver the findings during the conference’s Phase II/III clinical trials session.

Pulse Analysis

Gastroesophageal cancer remains one of the most aggressive solid tumors, and patients whose disease progresses after PD‑1 blockade face a stark therapeutic void. Standard chemotherapy offers modest survival gains, while emerging checkpoint inhibitors have yet to demonstrate durable responses in this refractory setting. Consequently, biotech firms are racing to develop combination regimens that can re‑activate immune surveillance and overcome tumor immune evasion mechanisms.

Agenus’ approach leverages three distinct immunologic modalities: botensilimab, an Fc‑enhanced anti‑CTLA‑4 antibody that amplifies both innate and adaptive immunity; balstilimab, a fully human PD‑1 antagonist with a favorable safety profile; and agenT‑797, an allogeneic invariant natural killer T (iNKT) cell therapy designed to provide a rapid, off‑the‑shelf cellular attack. Pre‑clinical data suggest that synchronizing checkpoint inhibition with iNKT‑mediated cytotoxicity can remodel the tumor microenvironment, converting “cold” lesions into inflamed targets. Early‑phase trials have already exposed more than 2,100 patients to BOT and BAL, reporting response signals across nine metastatic cancers, which bolsters confidence in the triple‑combo’s translational potential.

The upcoming AACR presentation will be a litmus test for investors and competitors alike. If the Phase II data demonstrate meaningful response rates or durability, Agenus could accelerate regulatory discussions and position its platform as a viable alternative to larger checkpoint‑inhibitor manufacturers. Moreover, a successful outcome may catalyze partnership talks, expand the company’s market cap, and influence treatment sequencing guidelines for refractory gastroesophageal malignancies. As the immuno‑oncology field pivots toward multi‑agent strategies, Agenus’ data could reshape the competitive landscape and set new benchmarks for combination cell‑based therapies.